This is of particular importance since the thrombin-PAR-1 pathway is an attractive target for the development of novel therapeutics for ischemic stroke (13, 19, 22, 23, 34–36) and may potentially prevent secondary thrombin-related brain damage. This evidence concerns the gene F2R and ischemic stroke.